Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins

Luis Querol, Ricard Rojas-García, Jordi Diaz-Manera, Joseba Barcena, Julio Pardo, Angel Ortega-Moreno, Maria Jose Sedano, Laia Seró-Ballesteros, Alejandra Carvajal, Nicolau Ortiz, Eduard Gallardo, Isabel Illa

Research output: Contribution to journalArticleResearchpeer-review

167 Citations (Scopus)


Objective: To describe the response to rituximab in patients with treatment-resistant chronic inflammatory demyelinating polyneuropathy (CIDP) with antibodies against paranodal proteins and correlate the response with autoantibody titers. Methods: Patients with CIDP and IgG4 anti-contactin-1 (CNTN1) or anti-neurofascin-155 (NF155) antibodies who were resistant to IV immunoglobulin and corticosteroids were treated with rituximab and followed prospectively. Immunocytochemistry was used to detect anti-CNTN1 and anti-NF155 antibodies and ELISA with human recombinant CNTN1 and NF155 proteins was used to determine antibody titers. Results: Two patients had a marked improvement; another patient improved slightly after 10 years of stable, severe disease; and the fourth patient had an ischemic stroke unrelated to treatment and was lost to follow-up. Autoantibodies decreased in all patients after rituximab treatment. Conclusions: Rituximab treatment is an option for patients with CIDP with IgG4 anti-CNTN1/NF155 antibodies who are resistant to conventional therapies. Classification of evidence: This study provides Class IV evidence that rituximab is effective for patients with treatment-resistant CIDP with IgG4 anti-CNTN1 or anti-NF155 antibodies.
Original languageEnglish
Pages (from-to)e149
JournalNeurology: Neuroimmunology and NeuroInflammation
Issue number5
Publication statusPublished - 1 Oct 2015


Dive into the research topics of 'Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins'. Together they form a unique fingerprint.

Cite this